UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay

Familial cancer, 2021-10, Vol.20 (4), p.363-380

2021

Volltextzugriff (PDF)

Lésion intracrânienne révélatrice d’une maladie de Hodgkin

Revue neurologique, 2008-02, Vol.164 (2), p.200-205

2008

Volltextzugriff (PDF)

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Leukemia, 2013-06, Vol.27 (6), p.1283-1290

2013

Volltextzugriff (PDF)

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Leukemia, 2012-06, Vol.26 (6), p.1286-1292

2012

Volltextzugriff (PDF)

P1556: HYPER ‐FERRITINEMIA IN PEDIATRIC ONCOLOGY PATIENTS SECONDARY TO TREATMENT: DIAGNOSTIC APPROACH AND OUTCOME

HemaSphere, 2022-06, Vol.6 (Suppl), p.1437-1438

2022

Volltextzugriff (PDF)

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas

Leukemia, 2004-10, Vol.18 (10), p.1711-1716

2004

Volltextzugriff (PDF)

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A

Leukemia research, 2018-08, Vol.71, p.67-74

2018

Volltextzugriff (PDF)

Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond

Expert opinion on biological therapy, 2010-04, Vol.10 (4), p.605-614

2010

Volltextzugriff (PDF)

P821: LATE ONSET AND/OR LONG LASTING NEUTROPENIA IN CHILDHOOD: CLINICAL AND HEMATOLOGICAL CHARACTERISTICS AND OUTCOMES

HemaSphere, 2022-06, Vol.6 (Suppl), p.715-716

2022

Volltextzugriff (PDF)

P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1581-1582

2022

Volltextzugriff (PDF)

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Annals of hematology, 2013-05, Vol.92 (5), p.621-631

2013

Volltextzugriff (PDF)

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS

HemaSphere, 2022-06, Vol.6 (Suppl), p.1793-1794

2022

Volltextzugriff (PDF)

Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine

Clinical infectious diseases, 2003-12, Vol.37 (12), p.e174-e176

2003

Volltextzugriff (PDF)

Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

Leukemia research, 2017-04, Vol.55, p.S33-S33

2017

Volltextzugriff (PDF)

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

Leukemia research, 2008-07, Vol.32 (7), p.1049-1053

2008

Volltextzugriff (PDF)

PML-RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

Leukemia, 2010-02, Vol.24 (2), p.473-476

2010

Volltextzugriff (PDF)

205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U)

Leukemia research, 2015-04, Vol.39, p.S102-S102

2015

Volltextzugriff (PDF)

Acute colchicine intoxication during clarithromycin administration

The Annals of pharmacotherapy, 2004-12, Vol.38 (12), p.2074

2004

Volltextzugriff (PDF)

Treatment of acute promyelocytic leukemia with high white cell blood counts

Mediterranean journal of hematology and infectious diseases, 2011-01, Vol.3 (1), p.e2011038-e2011038

2011

Volltextzugriff (PDF)

81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES

Leukemia research, 2015-04, Vol.39, p.S39-S40

2015

Volltextzugriff (PDF)

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS

Leukemia research, 2011-11, Vol.35 (11), p.1530-1533

2011

Volltextzugriff (PDF)

Analysis of rare driving events in pediatric acute myeloid leukemia

Haematologica (Roma), 2023-01, Vol.108 (1), p.48

2023

Volltextzugriff (PDF)

P-213 Impact of individual cytogenetic abnormalities, IPSS-R karyotype and monosomal karyotype on outcomes after allogeneic HCT for MDS/sAML

Leukemia research, 2013-05, Vol.37, p.S119-S120

2013

Volltextzugriff (PDF)

Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Annals of hematology, 2013-05, Vol.92 (5), p.633-633

2013

Volltextzugriff (PDF)

99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients

Leukemia research, 2011, Vol.35, p.S37-S38

2011

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(62)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(26)
Hematology
(20)
Male
(18)
Female
(16)
Oncology
(15)
Adult
(14)
Hematology, Oncology And Palliative Medicine
(13)
Aged
(12)
Middle Aged
(11)
Biological And Medical Sciences
(8)
Child
(8)
Medical Sciences
(8)
Aged, 80 And Over
(6)
Prognosis
(6)
Treatment Outcome
(6)
Hematologic And Hematopoietic Diseases
(5)
Immunology
(5)
Myelodysplastic Syndromes
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay

Lésion intracrânienne révélatrice d’une maladie de Hodgkin

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

P1556: HYPER ‐FERRITINEMIA IN PEDIATRIC ONCOLOGY PATIENTS SECONDARY TO TREATMENT: DIAGNOSTIC APPROACH AND OUTCOME

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A

Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond

P821: LATE ONSET AND/OR LONG LASTING NEUTROPENIA IN CHILDHOOD: CLINICAL AND HEMATOLOGICAL CHARACTERISTICS AND OUTCOMES

P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS

Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine

Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

PML-RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U)

Acute colchicine intoxication during clarithromycin administration

Treatment of acute promyelocytic leukemia with high white cell blood counts

81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS

Analysis of rare driving events in pediatric acute myeloid leukemia

P-213 Impact of individual cytogenetic abnormalities, IPSS-R karyotype and monosomal karyotype on outcomes after allogeneic HCT for MDS/sAML

Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients

Suchergebnisse filtern